252 related articles for article (PubMed ID: 25447672)
1. Structural changes of the ligand and of the receptor alters the receptor preference for neutrophil activating peptides starting with a formylmethionyl group.
Forsman H; Winther M; Gabl M; Skovbakke SL; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2015 Jan; 1853(1):192-200. PubMed ID: 25447672
[TBL] [Abstract][Full Text] [Related]
2. Structural Determinants in the
Viklund M; Fredriksson J; Holdfeldt A; Lind S; Franzyk H; Dahlgren C; Sundqvist M; Forsman H
J Immunol; 2022 Apr; 208(7):1632-1641. PubMed ID: 35321878
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization and inhibitory profile of formyl peptide receptor 2 selective peptides descending from a PIP2-binding domain of gelsolin.
Forsman H; Andréasson E; Karlsson J; Boulay F; Rabiet MJ; Dahlgren C
J Immunol; 2012 Jul; 189(2):629-37. PubMed ID: 22706076
[TBL] [Abstract][Full Text] [Related]
4. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands.
He HQ; Troksa EL; Caltabiano G; Pardo L; Ye RD
J Biol Chem; 2014 Jan; 289(4):2295-306. PubMed ID: 24285541
[TBL] [Abstract][Full Text] [Related]
6. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
Kretschmer D; Rautenberg M; Linke D; Peschel A
J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
[TBL] [Abstract][Full Text] [Related]
7. Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages.
Marutani T; Nishino K; Miyaji T; Kamada K; Ohura K; Kiso Y; Mukai H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920954
[TBL] [Abstract][Full Text] [Related]
8. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors.
Forsman H; Dahlgren C
Scand J Immunol; 2009 Oct; 70(4):396-402. PubMed ID: 19751275
[TBL] [Abstract][Full Text] [Related]
9. The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop.
Forsman H; Bylund J; Oprea TI; Karlsson A; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2013 Aug; 1833(8):1914-23. PubMed ID: 23562731
[TBL] [Abstract][Full Text] [Related]
10. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
11. Identification of Residues Critical for FPR2 Activation by the Cryptic Peptide Mitocryptide-2 Originating from the Mitochondrial DNA-Encoded Cytochrome
Lind S; Gabl M; Holdfeldt A; Mårtensson J; Sundqvist M; Nishino K; Dahlgren C; Mukai H; Forsman H
J Immunol; 2019 May; 202(9):2710-2719. PubMed ID: 30902901
[TBL] [Abstract][Full Text] [Related]
12. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
Stepniewski TM; Filipek S
Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522
[TBL] [Abstract][Full Text] [Related]
13. A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead.
Winther M; Gabl M; Welin A; Dahlgren C; Forsman H
FEBS Lett; 2015 Jul; 589(15):1832-9. PubMed ID: 26071379
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of ligand binding modes at the human formyl peptide receptor 2.
Chen T; Xiong M; Zong X; Ge Y; Zhang H; Wang M; Won Han G; Yi C; Ma L; Ye RD; Xu Y; Zhao Q; Wu B
Nat Commun; 2020 Mar; 11(1):1208. PubMed ID: 32139677
[TBL] [Abstract][Full Text] [Related]
15. The proteolytically stable peptidomimetic Pam-(Lys-βNSpe)6-NH2 selectively inhibits human neutrophil activation via formyl peptide receptor 2.
Skovbakke SL; Heegaard PM; Larsen CJ; Franzyk H; Forsman H; Dahlgren C
Biochem Pharmacol; 2015 Jan; 93(2):182-95. PubMed ID: 25462815
[TBL] [Abstract][Full Text] [Related]
16.
Sundqvist M; Christenson K; Gabl M; Holdfeldt A; Jennbacken K; Møller TC; Dahlgren C; Forsman H
J Immunol; 2019 Dec; 203(12):3349-3360. PubMed ID: 31694908
[TBL] [Abstract][Full Text] [Related]
17. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
Lacivita E; Schepetkin IA; Stama ML; Kirpotina LN; Colabufo NA; Perrone R; Khlebnikov AI; Quinn MT; Leopoldo M
Bioorg Med Chem; 2015 Jul; 23(14):3913-24. PubMed ID: 25549897
[TBL] [Abstract][Full Text] [Related]
18. Formylated MHC Class Ib Binding Peptides Activate Both Human and Mouse Neutrophils Primarily through Formyl Peptide Receptor 1.
Winther M; Holdfeldt A; Gabl M; Wang JM; Forsman H; Dahlgren C
PLoS One; 2016; 11(12):e0167529. PubMed ID: 27907124
[TBL] [Abstract][Full Text] [Related]
19. Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1.
Liu FC; Yu HP; Syu YT; Fang JY; Lin CF; Chang SH; Lee YT; Hwang TL
Sci Rep; 2017 Jul; 7(1):6718. PubMed ID: 28751674
[TBL] [Abstract][Full Text] [Related]
20. Formyl peptide derived lipopeptides disclose differences between the receptors in mouse and men and call the pepducin concept in question.
Winther M; Holdfeldt A; Sundqvist M; Rajabkhani Z; Gabl M; Bylund J; Dahlgren C; Forsman H
PLoS One; 2017; 12(9):e0185132. PubMed ID: 28934373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
